Safety and Tolerability of Oseltamivir Prophylaxis in Hematopoietic Stem Cell Transplant Recipients: A Retrospective Case-Control Study | Zendy

D. Vu | Zendy; Alexandra Peck | Zendy; W. Garrett Nichols | Zendy; Cara D. Varley | Zendy; J. A. Englund | Zendy; Lawrence Corey | Zendy; Michael Boeckh | Zendy

Open Access

Safety and Tolerability of Oseltamivir Prophylaxis in Hematopoietic Stem Cell Transplant Recipients: A Retrospective Case-Control Study

Author(s) -

D. Vu,

Alexandra Peck,

W. Garrett Nichols,

Cara D. Varley,

J. A. Englund,

Lawrence Corey,

Michael Boeckh

Publication year - 2007

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/518985

Subject(s) - medicine , oseltamivir , adverse effect , serostatus , hematopoietic stem cell transplantation , common terminology criteria for adverse events , surgery , pediatrics , transplantation , immunology , viral load , infectious disease (medical specialty) , disease , covid-19 , human immunodeficiency virus (hiv)

Oseltamivir is safe and effective in immunocompetent persons, and prophylactic use is recommended during influenza outbreaks. However, no data exist regarding the use of oseltamivir as prophylaxis among patients undergoing hematopoietic stem cell transplantation (HSCT).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research